Member Info for Mars1

Value £618m. Posted 24/11
“ the number of active participants will typically be approximately 450 000, although we will only be testing approximately 100 000 a week. All participants shall be swab tested and up to 20 % of participants shall also receive blood tests for antibodies. Participants receive testing on a weekly basis for the first 5 weeks they are on the study, before moving to monthly testing for a year”
https://bidstats.uk/tenders/2020/W48/739573790

Fearful pi’s , ODX is operating profitably anyway, positive cash flow last year just have to ramp up those numbers if your out good luck

Lagmassive is that 110,000 boxes x10 per box so 1,100,000 in stock

Anyone Tier 3 has access to 20 min test

Yes the abc19 website has been updated. Maybe someone can contact one of the RTC . The last update re the FDA approval I believe was for laboratories and health workers the website only says labs.
“

Twattcher you have left out the labour cost from the 75p

38bn this year and 55bn next year
It confirms an additional £38 billion for public services to continue to fight the pandemic this year, and a further £55 billion to departments to respond to Covid-19 next year,

Contract award is dated 2/11

Ciga’s tweet re 3bn tests came after the contract award on 2/11

Not a tender it is a contract award dated 2/11

Contract award notice £20bn
https://ted.europa.eu/udl?uri=TED:NOTICE:523069-2020:TEXT:EN:HTML&tabId=1

Looking at the current product list of Sosei they do not have a solution for nausea and vomiting for cancer patients , it looks like APD403 was not progressed past the final phase.

This was never just a COVID play with global HIV and food tolerance tests but it is now a non COVID play in domestic terms as Han**** has said he wants to grow diagnostics and maintain a much larger infrastructure to meet other ongoing and future requirements. Production was never going to tail off the future is bright and a long term play.

From the RNS in May 2019 one year earlier
“ NXP001 is in development as a treatment for chemotherapy-induced nausea and vomiting ("CINV"), a large, under-exploited and growing market, which in demographic terms comprises one third of global cancer patients.
In a pilot study in healthy subjects, a proprietary cocrystal-based formulation developed within the NXP001 programme demonstrated bioequivalence to Merck's EMEND® at 125mg both in terms of peak exposure and overall exposure (Cmax and AUC).
The positive results from the trial now enable the Company to:
· Confirm NXP001's potential for development as a treatment for CINV, enabling current and future licensees to launch new products into the £16bn oncology supportive care market”

40bn just to manufacture tests, so at £8 a test 5bn tests, and a much more active diagnostics industry following COVID to continue with an increased infrastructure.
https://www.dailymail.co.uk/news/article-8981739/Matt-Han****-claims-Tier-Three-restrictions-lockdown-werent-tough-enough.html

From the business update RNS in May
“ Nuformix is now open to discussions with other third parties regarding the licensing of global rights to NXP001 and is currently following up interest with one such party in particular. ”

“The self test does mention "to determine if an individual is immune to SARS-CoV-2", but wouldn't vaccine effectiveness monitoring be on a POC basis ?”
This would apply in no immune certification was available. So with any mass activity a test will be necessary, so antibody if vaccinated or had it and antigen if not eg theatre cinema football rugby etc. It does leave the question what happens to the 10/30% that may not take the vaccine antibodies

OBWiser it appears let’s hope NXP001 is point 4

It is the micro cap index, any funds investing in micro caps will either compete or track index so therefore cannot ignore any constituent of the index

Here is the press release from Sosei, the 4th point for raising the funds is interesting. “ o in-licensing late-stage clinical assets to develop for the Japanese market“, as far as I am aware there has been no announcement regarding this target.
https://soseiheptares.com/investors/newsroom/press-releases.html